According to previous studies, PI3K signaling pathway inhibitors may increase the sensitivity of tumor cells to chemotherapy by changing the peripheral vascular system and tumor perfusion, thereby increasing the efficacy of systemic therapy and inducing apoptosis.229 Early clinical studies showed that PI3K pathway inhibitors are well tolerated when administered with chemotherapy; pictilisib, carboplatin, and paclitaxel have shown good antitumor activity in patients with NSCLC. The gene discussed is PIK3CB; the disease is neoplasm.